New Delhi: Unichem Laboratories said it has entered into a settlement pact with pharma major Eli Lilly & Company and ICOS Corporation for resolving their patent litigation regarding generic tadalafil used for treating erectile dysfunction.
The patent litigation was in the US District Court for New Jersey, Unichem said.
The company “has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the US District Court for District of New Jersey regarding Unichem’s Abbreviated New Drug Application for generic tadalafil (CialisB),” it said in a BSE filing.
Under the agreement, Unichem expects to launch its generic tadalafil product in the US on or not before March 26, 2019, under certain circumstances, the company said.
It, however, did not provide any details about the ‘certain circumstances’.